fundladderEvery way to raise money, home page

I run a life sciences, biotech or medtech business

Grants, R&D relief and the specialist investors behind long, costly research, cheapest first.

Last checked: 10 October 2026

Life sciences businesses can spend years and large sums on research, trials and approvals before they sell anything. Few lenders will fund that, so the money usually comes from grants, R&D tax relief and investors who understand the science and the timescales.

Under the merged R&D scheme, for accounting periods starting on or after 1 April 2024, the R&D expenditure credit is 20%. Loss-making small companies that spend at least 30% of their total costs on R&D may claim enhanced support instead. Later on, some companies raise money on a stock market.

19 routes to look at, cheapest first

Compare the first 4 side by side
  1. L0

    Free or nearly free

    Little or no cash cost, though most take time and admin. Some bring money in, and a few have small fees.
  2. L2

    Mainstream secured debt

    Standard borrowing from banks and mainstream lenders, often secured on assets or backed by a personal guarantee.
  3. L3

    Specialist secured debt

    Borrowing secured on specific assets such as invoices or stock, with more fees and conditions than mainstream debt.
  4. Equity rungs. These routes cost no interest, but you give up part of the ownership and control of your business. They are ranked by how much you give up, not by a made-up interest rate. Over time, equity can be the most expensive money of all.
    E1

    Light dilution

    You sell a small share of the company, usually to many small investors or people you know, and keep control of how it is run.
  5. E2

    Significant dilution and investor rights

    Investors take a meaningful stake and usually get rights such as a board seat, a veto over big decisions, or a preferred return.
  6. E3

    Major dilution, loss of control or public obligations

    Investors take control, or the company becomes publicly traded and takes on ongoing public rules, costs and scrutiny.

Worth knowing

Sources

  1. GOV.UK: R&D tax relief: the merged scheme and enhanced R&D intensive support (updated 8 January 2026) · checked 10 October 2026

Facts about each route are sourced on its own page.